Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast on MRI Outcomes in Active Psoriatic Arthritis
NCT03783026Phase 4Completed
- Sponsor
- Amgen
- Start
- Feb 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 4, open-label, single-arm trial of apremilast in psoriatic arthritis (PsA), sponsored by Amgen. Primary endpoint: Change From Baseline in the Composite Score of Bone Marrow Edema (BME), Synovitis, and Tenosynovitis Assessed by Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) at 24 weeks. Started Feb 2019; status: completed.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03783026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03783026.